(NASDAQ: MNMD) Mind Medicine's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.32%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.27%.
Mind Medicine's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast MNMD's revenue for 2026 to be $834,953,001, with the lowest MNMD revenue forecast at $834,953,001, and the highest MNMD revenue forecast at $834,953,001. On average, 3 Wall Street analysts forecast MNMD's revenue for 2027 to be $9,287,529,443, with the lowest MNMD revenue forecast at $2,814,866,307, and the highest MNMD revenue forecast at $16,570,096,990.
In 2028, MNMD is forecast to generate $21,919,417,665 in revenue, with the lowest revenue forecast at $7,803,917,162 and the highest revenue forecast at $39,225,844,000.